Citation Impact
Citing Papers
A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia
2018 StandoutNobel
Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung Cancer
2011
Chromatin modifiers and the promise of epigenetic therapy in acute leukemia
2014
Transition from inflammation to proliferation: a critical step during wound healing
2016 Standout
Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
2010
Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer
2014
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
2011 StandoutNature
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
A Perspective on Dietary Phytochemicals and Cancer Chemoprevention: Oxidative Stress, Nrf2, and Epigenomics
2012
Cancer stem cells revisited
2017 Standout
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
2010 Standout
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
2010
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Coumarins: Old Compounds with Novel Promising Therapeutic Perspectives
2010 Standout
Epigenetic treatment of solid tumours: a review of clinical trials
2015
Light‐Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy
2015 StandoutNobel
TET enzymes, TDG and the dynamics of DNA demethylation
2013 StandoutNature
Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia
2009
Epigenetic modifications as therapeutic targets
2010
Leukaemogenesis: more than mutant genes
2009
Therapy with azanucleosides for myelodysplastic syndromes
2010
Epigenetic modifications and human disease
2010 Standout
A decade of exploring the cancer epigenome — biological and translational implications
2011 Standout
The future of epigenetic therapy in solid tumours—lessons from the past
2013
Differentiation therapy of leukemia: 3 decades of development
2009
New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndrome
2011
Results of phase 2 randomized study of low‐dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia
2014
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
2015
Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates
2015
The emerging role of immune checkpoint based approaches in AML and MDS
2017 StandoutNobel
Combination therapy in combating cancer
2017 Standout
Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas
2010
Histone Deacetylase Inhibitors in Cancer Therapy
2009
Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed
2012
Liquid Biopsies: Genotyping Circulating Tumor DNA
2014 Standout
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
2018 Standout
Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure
2016
Drug Resistance in Cancer: An Overview
2014 Standout
Abrogation of TGF-β1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition
2009
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design
2011 Standout
Works of Eric Laille being referenced
Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study
2008
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).
2009
Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).
2007
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
2008
Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors
2008
Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
2011
Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors
2008